Hu Y, Wu Q, Liu B, et al. - Using optical coherence tomography (OCT), researchers assessed the edema reduction after intravitreal injection of ranibizumab (IVR) in two diabetic macular edema (DME) components in the same eye. Totally 113 eyes were included with mixed OCT pattern of DME. At baseline and follow-up visits (1, 3, and 6 months after 3 monthly consecutive IVR), all the eyes underwent best-corrected visual acuity (BCVA) examination and OCT scanning. Between baseline and follow-up visits, foveal thickness of the SRD component (SRDFT) and the non-SRD component (NSRDFT) was compared. At baseline, SRDFT was 265.6 ± 175.4 μm and decreased significantly at 1 month to 126.7 ± 114.4 μm, at 3 months to 110.5 ± 103.4 μm, and at 6 months to 110.4 ± 89.6 μm. At baseline, NSRDFT was 409.5 ± 173.1 μm and decreased significantly at 1 month to 274.1 ± 140.4 μm, at 3 months to 249.1 ± 95.9 μm, and at 6 months to 254.1 ± 90.4 μm. According to the optimized formula, IVR was effective in lessening both the SRD and non-SRD components of DME. In the SRD component, the connection between BCVA improvement and edema reduction was more significant.